Seroba Life Sciences
Venture Capital
Active
Dublin, Ireland
40
32M
26
2.67
8
0.35
8
- Stages of investment
- Areas of investment
Summary
The main department of described VC is located in the Dublin. The company was established in Europe in Ireland.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Seroba Life Sciences, startups are often financed by Imperial Innovations, Oxford Capital Partners, Nesta Ventures. The meaningful sponsors for the fund in investment in the same round are Enterprise Ireland, Inventages Venture Capital Investment Inc., Andera Partners. In the next rounds fund is usually obtained by Enterprise Ireland, Novartis Venture Fund, Roche Venture Fund.
The fund was created by Peter Sandys. The overall number of key employees were 4.
Among the most successful fund investment fields, there are Therapeutics, Medical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Ireland. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Fusion Pharmaceuticals, Atlantic Therapeutics, PQ Bypass. The fund has exact preference in some founders of portfolio startups.
The real fund results show that this VC is 11 percentage points more often commits exit comparing to other companies. The top activity for fund was in 2019. Opposing the other organizations, this Seroba Life Sciences works on 6 percentage points less the average amount of lead investments. Deals in the range of 10 - 50 millions dollars are the general things for fund. The top amount of exits for fund were in 2018. The fund is generally included in less than 2 deals every year.
Investor highlights
- Industry focus
- Stage focus
- Geo focus
- Check size
- 3M — 11M
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Last fund
- Fund size
- USD 134000000
- Fund raised date
- 2024-02-01
Analytics
- Total investments
- 40
- Lead investments
- 8
- Exits
- 8
- Rounds per year
- 2.67
- Follow on index
- 0.35
- Investments by industry
- Health Care (25)
- Biotechnology (25)
- Medical (23)
- Medical Device (13)
- Therapeutics (12) Show 19 more
- Investments by region
-
- United Kingdom (10)
- United States (6)
- Ireland (14)
- Canada (2)
- Switzerland (3) Show 3 more
- Peak activity year
- 2019
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Avg. valuation at time of investment
- 43M
- Group Appearance index
- 0.95
- Avg. company exit year
- 12
- Avg. multiplicator
- 2.96
- Strategy success index
- 0.40
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| 21 Jul 2021 | Biotechnology | Early Stage Venture | 38M | Brittany, Bretagne, France | |
| Easy Point Logistics | 16 Oct 2016 | Logistics, Information Technology | Seed | Region Metropolitana, Santiago, Chile | |
| Shorla Pharma | 04 Oct 2023 | Biotechnology, Pharmaceutical | Early Stage Venture | 35M | Ireland, County Tipperary, Ireland |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.